Use Case · Precision Medicine

Interrogate biomarker stratification evidence — genomics, proteomics, microbiome

PubMed-grounded biomedical AI that systematically challenges each pillar of a precision medicine argument. Built for clinical researchers, pharma R&D, and translational PhDs assessing what can reliably predict treatment response versus what remains unvalidated.

Try this workflow live

Pre-loaded BioSkepsis session built around pharmacogenomic and microbiome predictors of aspirin chemoprevention response in colorectal cancer.

See it in the app → Start free

Built for clinical and translational researchers

Clinical researchers: separate well-validated stratification biomarkers from underpowered or post-hoc findings before designing trials.
Pharma R&D scientists: assess biomarker hypotheses for Phase II/III trial enrichment, companion diagnostic strategy, and label restriction.
Translational PhDs and biotech research teams: ground hypothesis-driven biomarker work in verified literature with traceable PMIDs.

The 8-step workflow — biomarker claim to companion diagnostic feasibility

Each step systematically tests a pillar of the stratification argument. The workflow spans multiple biomarker modalities, then probes regulatory translation and health economics.

Enter a broad, multi-faceted research question

Pose a question that spans multiple biomarker types (e.g., genomics, proteomics, microbiome) and explicitly asks what can reliably predict individual treatment response versus what remains unvalidated.

Example query "Review whether pharmacogenomic or microbiome profiling before recommending aspirin chemoprevention could help predict who will benefit. Why do some patients show a 40% reduction in colorectal adenoma incidence while others derive no measurable benefit? What genetic variants (e.g., PIK3CA mutation status) or gut bacteria signatures have been linked to this variability?"

Review the initial AI synthesis

BioSkepsis runs Autopilot — refining the query, searching the corpus, shortlisting sources, and returning a structured, citation-grounded answer. Read through the sections, note which biomarker claims carry high vs. medium confidence ratings, and check the unverified citations panel at the bottom for flagged references with diagnostics.

Request the Research Landscape Synthesis

Ask BioSkepsis to generate a narrative overview of the precision medicine landscape for your target therapy. This produces:

A temporal map of how stratification evidence evolved (discovery, validation, translation phases)
The network structure connecting different biomarker modalities (genetics, microbiome, proteomics)
The mechanisms-to-outcomes chain linking molecular markers to clinical response
An assessment of replication patterns — where small-study findings have or have not held up at scale

Example query "Generate a cohesive Research Landscape Synthesis"

Challenge a biomarker claim from one modality

Identify a promising stratification biomarker that rests on a small or methodologically limited study. Ask whether any larger, more rigorous study has validated that biomarker prospectively for the clinical endpoint that matters.

Example query "A 2022 pilot study used a random forest model on 17 gut microbial features to distinguish aspirin chemoprevention responders from non-responders at AUC 0.92, but the cohort was only 60 patients and the endpoint was adenoma recurrence at 6 months. Has any study with over 200 participants validated a baseline stool microbiome signature for predicting long-term colorectal cancer risk reduction with aspirin prospectively, before treatment begins?"

Challenge a biomarker claim from a different modality

Identify another candidate predictor from a different data type (e.g., proteomics instead of genomics) and ask whether it is truly predictive at baseline or merely descriptive after treatment. Probe whether the study design answers the stratification question or a different question that has been conflated with it.

Example query "A 2023 proteomic analysis of long-term aspirin users found a 30-protein inflammation signature at AUC 0.94, but that was measured after years of treatment, not at baseline. Have any of those 30 proteins, or a subset, been measured at baseline and tested as pre-treatment predictors of who will derive the greatest chemopreventive benefit?"

Probe the regulatory pathway for companion diagnostics

Ask what regulatory precedent exists for translating the proposed biomarker panel into a clinical-grade companion diagnostic. This tests whether the science can realistically move from bench to bedside.

Example query "What regulatory precedent exists for FDA or EMA approval of companion diagnostics that combine genetic and microbiome biomarkers to guide prescribing of a specific drug class?"

Probe the health-economic case for stratified prescribing

Ask about the cost-effectiveness of pre-treatment profiling versus the waste from prescribing to non-responders. BioSkepsis will surface whatever pharmacoeconomic evidence exists and transparently report where specific figures are absent.

Example query "What is the estimated cost per patient of pre-treatment microbiome sequencing plus a PIK3CA panel versus the QALY benefit of recommending aspirin chemoprevention to a non-responder over 10 years?"

Confirm a key clinical benchmark

Use one of the suggested follow-up buttons or type a simple factual question to nail down a specific real-world number that underpins the economic or clinical case for stratification.

Example query "What is the adherence rate for daily aspirin chemoprevention at 5 years in real-world clinical cohorts?"

What you walk away with

Confidence-rated biomarker claims

Each claim graded on study size, design, prospective vs. retrospective measurement, and replication.

Multi-modality landscape

How genetics, microbiome, and proteomics intersect — and where replication is missing.

Regulatory feasibility check

Companion diagnostic precedents for combining biomarker modalities under FDA / EMA.

Health-economic grounding

Cost-effectiveness evidence and adherence benchmarks for stratified prescribing.

Walk through the live workflow

Pre-loaded BioSkepsis session walking through biomarker interrogation across genomics, proteomics, and microbiome modalities.

See it in the app →

Honest limits — what AI will not do for precision medicine

AI cannot generate biomarker evidence that does not exist. If a stratification claim has only one underpowered study, BioSkepsis will say so — not invent confirmation.
AI does not replace biostatistical review. Multiple-testing correction, batch effects, confounders, and study design assessment require trained methodologists.
AI cannot evaluate unpublished cohorts. Internal pharma datasets and ongoing trials are not in the corpus until published. The literature reflects what has been disclosed.
Final review remains human. Every claim should be verified against the cited source before inclusion in a regulatory submission, trial protocol, or publication.

Frequently asked questions

What biomarker modalities does BioSkepsis cover?

Genomics (SNPs, gene expression, GWAS hits), proteomics (single proteins, panels, signatures), transcriptomics (bulk and single-cell), epigenomics (methylation, histone marks), microbiome (16S, shotgun metagenomic, metabolomic), and multi-omic integrations. The corpus draws from PubMed, biorxiv, and medrxiv across all major biomedical journals.

How does BioSkepsis distinguish high-confidence from low-confidence biomarker claims?

Each claim receives a confidence rating based on study size, design rigor, prospective vs. retrospective measurement, replication across cohorts, and validation in independent populations. The unverified citations panel separately flags claims where the cited source does not actually support the assertion.

Can BioSkepsis surface regulatory precedents for companion diagnostics?

Yes. Step 6 of the workflow probes published FDA and EMA precedents for combining multiple biomarker modalities (e.g., genomic + microbiome) into clinical-grade companion diagnostics. BioSkepsis surfaces what regulatory paths have been precedented and where current proposals lack analogue.

Is the workflow suitable for pharmacoeconomic analysis?

Step 7 of the workflow surfaces pharmacoeconomic evidence on cost-effectiveness of pre-treatment profiling versus the waste from prescribing to non-responders. Where specific figures are absent in the literature, BioSkepsis transparently reports this rather than estimating.

Does BioSkepsis cover real-world adherence and outcomes data?

Yes — the corpus includes real-world evidence studies, registry analyses, claims data publications, and pragmatic clinical trials. Step 8 of the workflow nails down specific real-world numbers (adherence rates, discontinuation, dose modifications) that underpin the economic or clinical case for stratification.

Interrogate your next precision medicine hypothesis

40M+ curated biomedical papers. PubMed-grounded. Confidence-rated biomarker claims. Free tier — no credit card.

See it in the app Start free